FADS1 and metabolic dysfunction-associated steatotic liver disease: Our observations suggest that the activation of FADS1 expression, as a proxy for icosapent ethyl treatment, confers a protective effect against MASLD, which can be attributed to several biochemical and metabolic mechanisms.